[HTML][HTML] First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine …
MJ Smit, AF Sander, MBPA Ariaans… - The Lancet …, 2023 - thelancet.com
Background Capsid virus-like particles (cVLP) have proven safe and immunogenic and can
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.
MJ Smit, AF Sander, MBPA Ariaans, C Fougeroux… - 2023 - cabidigitallibrary.org
Background: Capsid virus-like particles (cVLP) have proven safe and immunogenic and can
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
[HTML][HTML] First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine …
MJ Smit, AF Sander, MBPA Ariaans… - The Lancet …, 2023 - ncbi.nlm.nih.gov
Background Capsid virus-like particles (cVLP) have proven safe and immunogenic and can
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2
MJ Smit, AF Sander, MBPA Ariaans… - The Lancet …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Capsid virus-like particles (cVLP) have proven safe and immunogenic and can
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.
MJ Smit, AF Sander, M Ariaans, C Fougeroux… - The Lancet …, 2023 - europepmc.org
Background Capsid virus-like particles (cVLP) have proven safe and immunogenic and can
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
[PDF][PDF] First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2
MJ Smit, AF Sander, MBPA Ariaans, C Fougeroux… - 2023 - academia.edu
Background Capsid virus-like particles (cVLP) have proven safe and immunogenic and can
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
[PDF][PDF] First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.
MJ Smit, AF Sander, M Ariaans, C Fougeroux… - 2023 - repository.ubn.ru.nl
BACKGROUND: Capsid virus-like particles (cVLP) have proven safe and immunogenic and
can be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
can be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2
MJ Smit, AF Sander, MBPA Ariaans… - Lancet …, 2023 - ub01.uni-tuebingen.de
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised,
phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2 First-in-human use of a modular …
phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2 First-in-human use of a modular …
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2
COUGH-1 trial study group - The Lancet Microbe, 2023 - pure.au.dk
BACKGROUND: Capsid virus-like particles (cVLP) have proven safe and immunogenic and
can be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
can be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2
MJ Smit, AF Sander, MBPA Ariaans… - The Lancet …, 2023 - research.regionh.dk
BACKGROUND: Capsid virus-like particles (cVLP) have proven safe and immunogenic and
can be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …
can be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP …